Entrectinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ENTRECTINIB |
|---|---|
| Type | Drug |
| Aliases | RozlytrekЕнтректініб |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | ROS1 / NTRK / ALK TKI (CNS-penetrant) |
|---|---|
| Mechanism | Multi-kinase inhibitor (TRKA/B/C / ROS1 / ALK) with high CNS penetration. Tumor-agnostic NTRK-fusion indication; 1L preferred for ROS1+ NSCLC per ESMO. |
| Typical dosing | 600 mg PO once daily. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
STARTRK-2: tumor-agnostic NTRK + ROS1 efficacy. Larotrectinib alternative for NTRK-only.
Used By
Regimens
REG-ENTRECTINIB-NSCLC- Entrectinib monotherapy (STARTRK-2) — ROS1+ NSCLC (CNS-active)